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Abstract 
Objective: To determine the rate of disease progression in a longitudinal natural history 
study of children with Charcot-Marie-Tooth disease (CMT). 
Methods: 206 (103 female) participants aged 3-20 years enrolled in the Inherited 
Neuropathies Consortium were assessed at baseline and 2-years. Demographic, 
anthropometric, and diagnostic information were collected. Disease progression was assessed 
with the CMT Pediatric Scale (CMTPedS), a reliable Rasch-built linearly weighted disability 
scale evaluating fine and gross motor function, strength, sensation, and balance.  
Results: On average CMTPedS Total scores progressed at a rate of 2.4±4.9 over 2-years 
(14% change from baseline, p<0.001). There was no difference between males and females 
(mean difference 0.5, 95%CI -0.9 to 1.9, p=0.49). The most responsive CMTPedS items were 
dorsiflexion strength (z-score change: -0.3, 95% CI -0.6 to -0.05, p=0.02), balance (z-score 
change: -1.0, 95% CI -1.9 to -0.09, p=0.03), and long jump (z-score change: -0.4, 95% CI -
0.7 to -0.02, p=0.04). Of the most common genetic subtypes, 111 participants with 
CMT1A/PMP22 duplication progressed by 1.8±4.2 (12% change from baseline, p<0.001), 
nine participants with CMT1B/MPZ mutation progressed by 2.2±5.1 (11% change), six 
participants with CMT2A/MFN2 mutation progressed by 6.2±7.9 (23% change), and seven 
participants with CMT4C/SH3TC2 mutations progressed by 3.0±4.5 (12% change). 
Participants with CMT2A progressed faster than CMT1A (mean difference -4.4, 95%CI -8.1 
to -0.8, p=0.02). Children with CMT1A progressed consistently through early childhood (3-
10 years) and adolescence (11-20 years) (mean difference 1.1, 95%CI -0.6 to 2.7, p=0.19) 
while CMT2A appeared to progress faster during early childhood than adolescence (mean 
difference 10.0, 95%CI -2.2 to 22.2, p=0.08).  
Interpretation: Using the CMTPedS as an outcome measure of disease severity, children 
with CMT progress at a significant rate over 2-years. Understanding the rate at which 
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children with CMT deteriorate is essential for adequately powering trials of disease-
modifying interventions.  
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Introduction 
Charcot-Marie-Tooth disease (CMT) is the eponym for inherited peripheral neuropathies and 
is among the most common inherited neurological disorders, affecting 1 in 1,214
1
 - 2,500
2
 
individuals of both sexes and all backgrounds. Mutations in more than 80 genes cause CMT 
(Inherited Neuropathy Variant Browser: 
http://hihg.med.miami.edu/code/http/cmt/public_html/index.html). The majority of CMT 
neuropathies are demyelinating, although up to one third appear to be primary axonal 
disorders.
3,4
 Despite a variable phenotype,
5
 most patients are characterized by onset in the 
first or second decade of life, with distal weakness, loss of sensation, and foot deformities 
(pes cavus and hammer toes). Progression slowly proceeds throughout one’s lifespan, 
although, some patients develop severe, rapidly progressing disability in early childhood (for 
example, Dejerine-Sottas neuropathy).
6
 Scientists are currently developing rational 
therapeutic strategies for a number of CMT subtypes. However, evaluating interventions in 
clinical trials remains limited in part by the slow progression of many CMT subtypes and by 
the lack of natural history data during the first two decades of life when significant 
progression appears to occur in many subtypes.
7
  
 
The CMT neuropathy score (CMTNS) versions 1 and 2 as well as the most recent Rasch 
analysis-based weighted version, rCMTNS, and the subscales rCMTES and rCMTSS are 
simple, reliable and validated standardized assessment tools for adults with CMT.
8,9
 However 
they show limited sensitivity in children, in part due to difficulties with cooperation for 
subjective components.
10
 The CMT Pediatric Scale (CMTPedS) is the only disease-specific 
scoring system available for children with CMT. The CMTPedS is a well-tolerated 
psychometrically robust 11-item clinical outcome measure assessing fine and gross motor 
function, strength, sensation and balance in children aged 3-20 years.
11
 The CMTPedS has 
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been subjected to classical test theory (item, reliability and factor analysis) and item response 
theory (Rasch modeling) to ensure it can reliably capture changes in disability over time. The 
CMTPedS is ideally suited to measure the natural history of CMT during childhood because 
it been shown to be sensitive to CMT genetic subtype, patient age and self-reported levels of 
pain and disability.
5
 
 
In a small longitudinal study of 15 affected children aged 4-17 years with mixed genetic 
subtypes, we reported a rate of disease progression of 1.0 CMTPedS points over 1-year (5% 
change from baseline).
11
 In a cross-sectional study of 520 patients with CMT, we observed in 
CMT1A that CMTPedS Total scores seemed to progress consistency throughout early 
childhood (aged 3-10 years) and adolescence (aged 11-20 years), while the rate of change in 
CMT1B, CMT2A and CMT4C seemed to be age-specific.
5
 Moreover, the cross-sectional 
studies suggested that the CMTPedS would be more sensitive to change than the Rasch 
weighted CMTNS scales in older children.
5
 In the present longitudinal study we extend these 
observations by using the CMTPedS to measure disease progression in a large cohort of 
children with predominantly CMT1A over a 2-year period.  
 
Materials and Methods 
Children aged 3-20 years enrolled across 8 sites of the Inherited Neuropathies Consortium, a 
member of the NIH Rare Disease Clinical Research Network 
(http://www.rarediseasesnetwork.org/), were assessed between August 2009 and September 
2016. The eight sites included:  Sydney Children’s Hospitals Network, University of Sydney, 
Australia; University of Iowa Health Care, Iowa, USA; Wayne State University, Detroit, 
USA; Children’s Hospital of Philadelphia, Pennsylvania, USA; Carlo Besta Neurological 
Institute IRCCS Foundation, Milan, Italy; National Hospital of Neurology and Neurosurgery 
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and Great Ormond Street Hospital, London, UK; Nemours Children’s Hospital, Florida, 
USA; University of Rochester, New York, USA. Human ethics or institutional review board 
approval was acquired from all institutions and written informed consent was obtained from 
all participants or their parents/guardians. All participants enrolled in the Inherited 
Neuropathies Consortium with a baseline and 2-year study visit (± 6 months) were included.  
 
Demographic, anthropometric, and physical characteristics including age, height, weight, 
CMT genotype, and self-reported symptoms (foot pain, leg cramps, unsteady ankles, daily 
trips and falls, hand pain, hand weakness, hand tremor, and sensory symptoms) were 
collected at each visit as described previously.
5
 Details of assistive device use (for example, 
ankle-foot orthoses, walkers, wheelchairs) and orthopedic surgery during the 2-year study 
period were also collected.  
 
Disability was assessed using the CMTPedS,
11
 a standardized clinical outcome measure 
comprising 11 performance-based items: Functional Dexterity Test; 9-Hole Peg Test; hand 
grip, foot dorsiflexion and plantarflexion strength by hand-held dynamometry; pinprick and 
vibration sensation; balance; gait; long jump; 6-minute walk test. Raw scores were converted 
to age- and sex-matched normative reference values from the 1000 Norms Project
12,13
 to 
obtain z-scores. Z-scores were categorized to a Likert scale ranging from 0 (unaffected) to 4 
(severely affected) i.e. 0 is within ±1 SD of normal, and a score of 1, 2, or 3 is 1-2, 2-3, or 3-4 
SDs below normative values respectively, and 4 is > 4 SDs below normal. These categorized 
scores are summed to produce a CMTPedS Total score between 0-44 (whereby 0 is least 
severe and 44 is most severe).
11
 A score of 0-14 is considered mildly affected, while 
moderate is defined as 15-29 and severe is 30-44 points on the CMTPedS. 
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Statistical analysis 
Data were analyzed using SPSS v. 22.0 (IBM Corp. Armonk, NY). All data were assessed for 
normality and the appropriate parametric or non-parametric test subsequently employed. 
Paired sample t-tests were calculated to assess the significance of change in CMTPedS Total 
and Item scores between baseline and 2-year study visit. A sensitivity analysis was performed 
to assess whether the variation in follow-up time around the 2 year study visit (± 6 months) 
had an effect on the rate of progression by calculating the rate of change over 2 years as the 
change score / number of weeks between visits x 104 weeks. We compared baseline to the 
second time point using a repeated measures ANCOVA with time to follow up as a covariate. 
Independent samples t tests were performed to evaluate differences between CMT subtypes, 
early childhood (aged 3-10 years) and adolescence (aged 11-20 years), males and females, 
and differences between children receiving or not receiving assistive devices or orthopedic 
surgery. An alpha level of 0.05 was used for statistical significance.  
 
Results 
Natural history data at baseline and 2-years were collected from 206 (103 female) children 
with CMT (mean follow-up 24.1±3.7 months). Baseline and 2-year demographic, 
anthropometric, self-report symptoms, and physical characteristics are presented in Table 1. 
As expected height and weight changed with age over 2 years (p<0.05), while BMI percentile 
and the number of self-report symptoms did not (p>0.05). Of the 15 CMT subtypes, the most 
prevalent were CMT1A (58%), CMT1B (5%), CMT2A (4%), and CMT4C (4%) (Table 2). 
While all children completed most items of the CMTPedS at baseline and 2-years, 187 
participants completed all items to obtain a CMTPedS Total score (Table 3). Participants 
unable to complete all items were due to reasons other than disease progression (for example 
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acute injury, behavioral issues). Their remaining item scores were used in the CMTPedS Item 
score analysis.  
 
Compared to children with CMT1A (14.6±7.1), baseline CMTPedS Total scores were 
significantly worse for CMT2A (26.7±9.6, mean difference -12.1, 95%CI -18.1 to -6.0, 
p<0.001) and CMT4C (26.1±11.5, mean difference -11.5, 95%CI -17.3 to -5.8, p<0.001). 
There was a borderline difference in baseline severity between children with CMT1B 
(19.4±5.2) and children with CMT1A (14.6±7.1) (mean difference -4.8, 95%CI -9.7 to 0.0, 
p=0.050) (Table 3). Age did not differ at baseline between any of these subtypes (p>0.05). 
 
Mean CMTPedS Total scores for the 187 children with all types of CMT progressed by 
2.4±4.9 over 2-years (p<0.001) (Table 3). In the sensitivity analysis, the mean CMTPedS 
Total scores progressed by 2.3±4.8 points between time points 1 and 2 (p<0.001). Overall 
males and females progressed at a similar rate (males 2.1±4.6, females 2.6±5.1, mean 
difference 0.5, 95%CI -0.9 to 1.9, p=0.49). There were no differences in the rate of 
progression of children who required orthopedic surgery (13 foot and ankle, 1 hand) or 
received assistive devices (11 ankle-foot orthoses, 1 walking aid, 2 wheelchair) during the 2-
year follow-up period (p>0.05) (Table 4). 
 
All individual items of the CMTPedS progressed over the 2-year period (Figure 1). The most 
responsive items were foot dorsiflexion strength (z-score change of -0.3, 95% CI -0.6 to -
0.05, p=0.02), balance (z-score change of -1.0, 95% CI -1.9 to -0.09, p=0.03), and long jump 
(z-score change of -0.4, 95% CI -0.7 to -0.02, p=0.04).  
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Of the four most common genetic subtypes in this study, 111 participants with 
CMT1A/PMP22 duplication progressed by 1.8±4.2 (12% change from baseline), nine 
participants with CMT1B/MPZ mutation progressed by 2.2±5.1 (11% change), six 
participants with CMT2A/MFN2 mutation progressed by 6.2±7.9 (23% change), and seven 
participants with CMT4C/SH3TC2 mutations progressed by 3.0±4.5 (12% change). While the 
rate of progression of CMT1A was highly significant (p<0.001), small numbers of CMT1B, 
CMT2A, and CMT4C cases precluded statistical significance (p>0.05). Children with 
CMT2A appeared to have progressed significantly faster than children with CMT1A (mean 
difference -4.4, 95%CI -8.1 to -0.8, p=0.02) (Figure 2). Table 3 shows the rate of change for 
other subtypes of CMT, although rate of progression for the smaller disease cohorts (for 
example, CMT2D/GARS mutation) should be interpreted with caution.  
 
As can also be seen in Figure 2, participants with CMT1A progressed at a consistent rate 
throughout childhood with no significant difference in the rate of disease progression 
between early childhood aged 3-10 years (2.4±4.4) and adolescence aged 11-20 years 
(1.4±4.0, mean difference 1.1, 95%CI -0.6 to 2.7, p=0.19). Younger children with CMT2A 
(9.5±7.8) appeared to progress faster than adolescents (-0.5±0.7) although this was not 
significant (mean difference 10.0, 95%CI -2.2 to 22.2, p=0.08). There was only one 
participant with CMT4C aged 3-10 years and six adolescents aged 11-20 years, which 
prevented comparison. The CMT1B data were highly variable.  
   
Discussion 
This is the first study to evaluate the 2-year natural history within and between genetic 
subtypes of CMT during childhood. Overall, children with CMT progressed at a rate of 2.4 
CMTPedS points, or 14%, and children with the most common form, CMT1A, progressed at 
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a rate of 1.8 CMTPedS points (12%). Children with CMT2A and CMT4C generally 
progressed at a faster rate than CMT1A, while progression of CMT1B was highly variable. 
The increased baseline severity scores of children with CMT1B, CMT2A and CMT4C 
compared to CMT1A is consistent with our previously reported cross-sectional analysis of 
520 participants.
5
  
 
For the CMT1A subtype, the rate of progression was stable throughout early childhood and 
adolescence, while other subtypes such as CMT2A appeared to progress faster during early 
childhood than adolescence. Males and females progressed at a similar rate in the most 
common subtypes of CMT. We were unable to evaluate the rate of progression in males vs. 
females with CMTX1 because there were no females with CMTX1 in our cohort, most likely 
due to them being mild or asymptomatic. It has been reported that males with CMTX1 
remain mildly affected until the second decade of life with increasing severity occurring in 
adulthood.
4
  
 
Therapeutic interventions are necessary to slow or halt the progression of CMT in pediatric 
patients. Previously there has been a lack of responsive outcome measures for clinical trials 
in patients with CMT, in part because of the slow progression of the most common 
subtypes.
14
 This longitudinal natural history study has shown that the CMTPedS is sensitive 
to the progression of CMT and would be an acceptable outcome measure for use in clinical 
trials. Rate of progression differed between the most common subtypes of CMT during 
childhood with CMT1A progressing slower than the other subtypes. Understanding the rate 
of change for each genetic subtype of CMT is essential to appropriately design and power 
future trials with gene-specific interventions. The rates reported in this study can be used to 
calculate the sample size for therapeutic trials. For example, it is estimated that for a 2-year 
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randomized (1:1), double-blind, parallel-group, placebo-controlled trial of an intervention 
aiming to halt the rate of CMT1A progression, a sample of 86 children per treatment arm 
would be required to provide 80% power (alpha 5%) to detect a difference between group 
means of 1.8 CMTPedS points (SD 4.2).
15
 Note: Adjustments would need to be made for 
correlation between pre-test and post-test scores, loss to follow-up and non-adherence. 
 
Despite the inclusion of a large international cohort of affected children evaluated 
prospectively with a well-validated clinical outcome measure over a period of 2-years, there 
are some limitations to this study. First, while the sample size for children with CMT1A was 
adequate, numbers for CMT1B, CMT2A, and CMT4C as well as for the rarer genetic 
subtypes (for example CMTX3, CMT1E, CMTX1, and CMT2D) preclude a conclusive 
determination of their natural history. Second, children younger than 3 years were excluded 
from the study because the CMTPedS is validated for children 3-20 years. The Inherited 
Neuropathies Consortium is currently developing and validating a CMT Infant Scale for 
affected patients aged 0-3 years.
16
  
 
In conclusion, children with CMT deteriorate significantly over 2-years. Genetic subtype has 
an influence on this rate of progression. Understanding the natural history of CMT, using 
well-validated scales like the CMTPedS, is essential for adequately powering clinical trials to 
alter disease progression.  
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Figure Legends: 
 
Figure 1: Baseline values and rate of progression for each CMTPedS Item score, based on 
age- and sex-matched normative reference values.
12,13
 Direction of item depends on unit of 
measure. Pinprick, Vibration and Gait are category scores because z-scores are not calculated 
for these items. All 206 participants completed Pinprick, Vibration, Balance and Gait items at 
baseline and 2-years; 205 completed the Functional Dexterity Test, 9-Hole Peg Test, long 
jump and 6 minute walk test; 196 complete grip strength and 194 completed plantarflexion 
and dorsiflexion strength.  *Significant change from baseline (p<0.05). 
 
Figure 2: CMTPedS Total score progression by CMT genetic subtype during early childhood 
(aged 3-10 years) and adolescence (11-20 years). Each slope represents an individual’s 
change in the CMTPedS Total score over 2-years.  
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Table 1:  Participant demographic, anthropometric and physical characteristics (n=206). 
 
Characteristic Baseline Follow-up Difference 
Age, yrs 
 
9.8±3.9  
(3 – 18) 
11.8±3.8  
(5 – 20)*  
2.0±1.1 
(95%CI, 1.3 – 2.8) 
Height, m 
 
1.40±0.22  
(0.90 – 1.83)  
1.49±0.20  
(0.97 – 1.93)*  
0.08±0.06 
(95%CI, 0.07 – 0.10)  
Weight, kg 
 
38.1±16.4  
(11.2 – 87.2) 
45.2±18.5  
(11.6 – 104.0)* 
7.1±5.5 
(95%CI, 6.2 – 7.9) 
BMI percentile 
 
53.8±33.0  
(0 – 98.9) 
53.1±33.0  
(0 – 99.0) 
-0.5±21.0 
(95%CI, -3.7 – 2.8) 
Self-reported symptoms 
(Sum of 8) 
3±2  
(0 – 8)  
3±2  
(0 – 8) 
0±2 
(95%CI, -0.2 – 0.3) 
Data are mean±SD (range) for baseline and follow-up scores and mean±SD (95% Confidence 
Interval) for Difference scores *Significant change from baseline (p<0.05). 
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Table 2: Frequency of CMT genetic subtypes in the cohort (n=206) 
 
CMT Type Number % of Cohort 
CMT1A, PMP22 duplication 119 58 
CMT1B, MPZ 10 5 
CMT1E, PMP22 point mutation 5 2 
CMT1F, NEFL 1 0.5 
CMT1, unknown 2 1 
CMT2A, MFN2 8 4 
CMT2D, GARS 3 1.5 
CMT2, unknown 8 4 
CMT4A, GDAP1 2 1 
CMT4B1, MTMR2 1 0.5 
CMT4C, SH3TC2 9 4 
CMT4F, PRX 1 0.5 
CMT4J, FIG4 1 0.5 
CMTX1, GJB1 4 2 
CMTX3, Xq27.1 insertion
17
 6 3 
HNPP, PMP22 deletion 2 1 
HSN 1 0.5 
Unknown 23 11 
Gene names following subtype if known. ‘CMT1 unknown’ indicates individuals with a 
demyelinating neuropathy without an underlying mutation being identified, while ‘CMT2 
unknown’ indicates individuals with an axonal neuropathy without an underlying genetic 
mutation. 
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Table 3:  Disease progression over 2-years according to the CMTPedS Total score by CMT 
genetic subtype. 
 
CMT type N 
Baseline 
Score 
Follow-
up Score 
Difference 
Change  
(% from 
baseline) 
All cases 187 17.3±9.1 
(1 – 40) 
19.6±9.4  
(0 – 42)  
2.4±4.9* 
(95%CI, 1.7 – 3.1) 
14 
CMT1A 111 14.6±7.1 
(1 – 39)  
16.4±6.9  
(0 – 36)  
1.8±4.2* 
(95%CI, 1.0 – 2.6) 
12 
CMT1B 9 19.4±5.2 
(14 – 30) 
21.7±6.6 
(13 – 35) 
2.2±5.1 
(95%CI, -1.7 – 6.1) 
11 
CMT1E 5 27.6±9.0 
(16 – 37) 
31.6±6.7 
(23 – 38)  
4.0±4.6 
(95%CI, -1.8 – 9.8)  
15 
CMT2A 6 26.7±9.6
#  
(14 – 36)
 
32.9±9.5  
(17 – 42)  
6.2±7.9
#
 
(95%CI, -2.2 – 14.5)
 
23 
CMT2D 3 22.3±7.2 
(14 – 27) 
28.7±12.7 
(14 – 36)  
6.3±5.5  
(95%CI, -7.4 – 20.0) 
28 
CMT2, 
unknown 
6 21.7±8.0 
(14 – 36) 
26.0±5.5 
(21 – 34) 
4.3±6.7 
(95%CI, -2.7 – 11.3) 
20 
CMT4C 7 26.1±11.5
#  
(8 – 38)
 
29.1±11.0 
(13 – 39) 
3.0±4.5 
(95%CI, -1.2 – 7.2) 
12 
CMTX1 4 9.8±8.2 
(1 – 19) 
12.3±10.0 
(1 – 25) 
2.5±3.0 
(95%CI, -2.3 – 7.3) 
26 
Unknown 22 20.8±11.1 
(2 – 40) 
22.7±10.2 
(5 – 38)  
1.9±6.9 
(95%CI, -1.1 – 5.0) 
9 
Data are mean±SD (range) for baseline and follow-up scores and mean±SD (95% Confidence 
Interval) for Difference scores. *Significant change from baseline (p<0.001), 
#
Significant 
difference to CMT1A (p=0.02). 
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Table 4:  CMTPedS Total scores for patients requiring assistive devices or orthopedic 
surgery during the 2-year follow-up.  
 
Intervention  N (%) Baseline 
Score 
Follow-up 
Score 
Difference Change 
(% from 
baseline) 
Assistive 
devices 
12 (6) 16.6±11.9 
(1 – 35)  
19.0±12.9 
(1 – 38)  
2.4±5.7* 
(95%CI, 0.3 –  6.0) 
12 
Orthopedic 
surgery 
14 (8) 20.4±9.3 
(7 – 39)  
23.3±7.6 
(14 – 37)  
2.9±4.3* 
(95%CI, 0.1 – 6.0) 
14 
No intervention  161 (86) 17.0±8.8 
(1 – 40) 
19.3±9.2 
(0 – 42) 
2.3±4.9*  
(95%CI, 0.5 – 3.0) 
14 
Data are mean±SD (range) for baseline and follow-up scores and mean±SD (95% Confidence 
Interval) for Difference scores. *Significant change from baseline (p<0.001). There was no 
significant difference between children requiring assistive devices or orthopedic surgery, and 
children who had no intervention in the baseline CMTPedS Total scores or rate of 
progression (p>0.05).  
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Figure 1: Baseline values and rate of progression for each CMTPedS Item score, based on age- and sex-
matched normative reference values.12,13 Direction of item depends on unit of measure. Pinprick, Vibration 
and Gait are category scores because z-scores are not calculated for these items. All 206 participants 
completed Pinprick, Vibration, Balance and Gait items at baseline and 2-years; 205 completed the Functional 
Dexterity Test, 9-Hole Peg Test, long jump and 6 minute walk test; 196 complete grip strength and 194 
completed plantarflexion and dorsiflexion strength.  *Significant change from baseline (p<0.05).  
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Figure 2: CMTPedS Total score progression by CMT genetic subtype during early childhood (aged 3-10 
years) and adolescence (11-20 years). Each slope represents an individual’s change in the CMTPedS Total 
score over 2-years.  
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